Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.

ABSTRACT:

Importance

Current treatments for idiopathic pulmonary fibrosis slow the rate of lung function decline, but may be associated with adverse events that affect medication adherence. In phase 2 trials, pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) attenuated the progression of idiopathic pulmonary fibrosis without substantial adverse events.

Objective

To assess the efficacy and safety of pamrevlumab for patients with idiopathic pulmonary fibrosis.

Design, setting, and participants

Phase 3 randomized clinical trial including 356 patients aged 40 to 85 years with idiopathic pulmonary fibrosis who were not receiving antifibrotic treatment with nintedanib or pirfenidone at enrollment. Patients were recruit

SUBMITTER: Raghu G 

PROVIDER: S-EPMC11304118 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature